Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Type of study
Language
Publication year range
1.
Free Radic Biol Med ; 96: 392-405, 2016 07.
Article in English | MEDLINE | ID: mdl-27156686

ABSTRACT

Monocyte-to-macrophage differentiation promotes an inflammatory environment within the arterial vessel wall that causes a mal-adaptive immune response, which contributes to the progression of atheromatous plaque formation. In the current study, we show that resveratrol, a well-known antioxidant, dose-dependently attenuated phorbol myristate acetate (PMA)-induced monocyte-to-macrophage differentiation, as measured by cell adhesion, increase in cell size, and scavenger receptor expression in THP-1 monocytes. Also, resveratrol significantly inhibited PMA-induced pro-inflammatory cytokine/chemokine and matrix metalloprotease (MMP-9) production. This inhibitory effect of resveratrol on monocyte differentiation results from its ability to restore intracellular glutathione (GSH) status, as resveratrol in the presence of buthionine sulfoximine (BSO) failed to affect monocyte differentiation. Furthermore, PMA-induced monocyte differentiation and inflammation was greatly inhibited when cells were co-treated with N-Acetyl-l-cysteine (NAC), a GSH precursor, while the presence of BSO aggravated these processes. These results also show that resveratrol mediated up-regulation of GSH is due to AMP-activated protein kinase (AMPK)-α activation, as compound C (AMPK inhibitor) treatment drastically depleted intracellular GSH and exacerbated PMA-induced monocyte differentiation and pro-inflammatory cytokine production. More importantly, chronic administration of resveratrol efficiently prevented monocyte infiltration and markedly diminished angiotensin (Ang)-II-induced atheromatous plaque formation in apolipoprotein-E knockout (ApoE(-/-)) mice. We conclude that, intracellular GSH status plays a critical role in regulating monocyte-to-macrophage differentiation and inflammation and resveratrol, by restoring GSH levels, inhibits these processes. Taken together, these results suggest that resveratrol can attenuate atherosclerosis, at least, in part, by inhibiting monocyte differentiation and pro-inflammatory cytokines production.


Subject(s)
Atherosclerosis/drug therapy , Glutathione/metabolism , Inflammation/drug therapy , Stilbenes/administration & dosage , AMP-Activated Protein Kinases/metabolism , Acetylcysteine/administration & dosage , Animals , Antioxidants/administration & dosage , Apolipoproteins E/genetics , Atherosclerosis/metabolism , Atherosclerosis/pathology , Buthionine Sulfoximine/administration & dosage , Cell Differentiation/drug effects , Homeostasis/drug effects , Humans , Inflammation/chemically induced , Inflammation/metabolism , Inflammation/pathology , Macrophages/drug effects , Matrix Metalloproteinase 9/biosynthesis , Mice , Mice, Knockout , Monocytes/drug effects , Resveratrol , Stilbenes/antagonists & inhibitors , Tetradecanoylphorbol Acetate/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL